An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma

Sponsor
Replimune, Inc.
Study ID
NCT06590480
Status
No Longer Available

Conditions

  • Advanced Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RP1 — BIOLOGICAL
    Genetically modified Herpes Simplex Type 1 Virus
  • Nivolumab — BIOLOGICAL
    Anti-PD-1 Monoclonal Antibody

Study Details

The purpose of this EAP is to provide expanded access (i.e., before marketing authorization) to vusolimogene oderparepvec (VO; herein referred to as VO) plus standard-of-care (SOC), nivolumab, for eligible patients diagnosed with advanced melanoma, who, in their treating physician's opinion, could benefit from this treatment.

Key Dates

Status verified
Dec 2025

Related Studies